HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
In this fifth year of anti-VEGF therapy for neovascular AMD, retinal physicians are
collecting groups of patients who either do not or only partially respond to anti-VEGF
therapy. This study will evaluate the efficacy and safety of 2mg ranibizumab specifically for
patients with fibrovascular PEDs that have not resolved following at least 6 consecutive
injections of ranibizumab or bevacizumab over the previous 12 months. The investigators
hypothesize that the 2mg dose will be able to completely eliminate the persistent PEDS in
these patients.